700560In situ 3D diffusion tracking for biomedical materialsClosedGRD Proof of MarketInnovate UKIn the healthcare screening sectors (drug discovery & biomedical materials) there is a pressing need for new quantitative monitoring technologies for in-vitro testing. Artificial 3D tissues, often in the form of 3D constructs such as liver mimics, are used to replicate the behaviour of real tissue and to track the diffusion of compounds, pharma-active species and cells in laboratory trials, thus improving the drug discovery process. However, their uptake has been limited by the inability to quantitatively measure the diffusion in real-time, non-invasively and cost effectively. Lein has combined its innovative scanning confocal technology, that is highly accurate, cost effective and very compact, with a fluorescence capability that enables the concentration of a compound to be detected at low nanomolar concentrations. This technology has been incorporated in a practical meter so that clinical researchers can assess the concentration of, and movement of, compounds within biological media. The strength of the meter is that it is able to make non-contact measurements enabling dynamic, in-situ testing. In this project Lein will analyse markets for this new technology. Relevant Key Opinion Leaders (academia, pharma companies, specialist life science companies) and potential customers will be interviewed and market needs, dynamics, drivers, barriers, competition, and potential size analysed to build a clear picture of the market opportunity. The outputs will be used to create a commercial exploitation plan, including market strategy and routes to market, and underpin the product development and funding raising plans.